Elevated Glycohemoglobin (HbA1c) Implications

Understanding HbA1c

• HbA1c forms when glucose attaches to the N-terminal valine residue of the hemoglobin β-chain, creating a stable ketoamine through an irreversible Amadori rearrangement 1
• HbA1c reflects average blood glucose levels over the previous 2-3 months, with recent glycemia having greater influence (50% from the past month, 25% from 30-60 days prior, and 25% from 60-120 days prior) 2, 3
• Each 1% increase in HbA1c corresponds to approximately 35 mg/dL (2 mmol/L) increase in mean plasma glucose 4

Health Consequences of Elevated HbA1c

Microvascular Complications

• Retinopathy: The Diabetes Control and Complications Trial (DCCT) demonstrated that elevated HbA1c increases retinopathy risk, with a 76% reduction in new retinopathy development when HbA1c was reduced by 1.8% 5
• Nephropathy: Elevated HbA1c increases risk of microalbuminuria (39% reduction with improved control) and progression to diabetic kidney disease 5, 6
• Neuropathy: Higher HbA1c levels are associated with 60% increased risk of developing clinical neuropathy 5

Macrovascular Complications

• Cardiovascular disease: Elevated HbA1c is associated with increased risk of cardiovascular events and mortality 6
• In patients with end-stage kidney disease, HbA1c levels ≥10% were associated with 41% higher all-cause mortality and 73% higher cardiovascular mortality compared to levels of 5-6% 6

U-shaped Mortality Risk

• Both very high (>8.5%) and very low (<6%) HbA1c levels are associated with increased mortality risk, particularly in patients with advanced chronic kidney disease 7, 6
• A meta-analysis of hemodialysis patients showed a U-shaped mortality curve with lowest risk at moderate HbA1c levels 7

Pathophysiological Mechanisms

• Chronic hyperglycemia causes glucose toxicity through multiple pathways, including increased oxidative stress and inflammatory mediators 6

Special Considerations and Confounding Factors

• Hemoglobin variants (e.g., HbS, HbC) can interfere with HbA1c measurements, causing falsely high or low results 2
• Conditions affecting red blood cell lifespan alter HbA1c independent of glycemia, such as shortened RBC lifespan (kidney disease, liver disease, hemolytic anemia, pregnancy) decreasing HbA1c, and prolonged RBC lifespan (iron deficiency anemia, aplastic anemia) increasing HbA1c 2, 5

Clinical Targets and Management

• For most adults with diabetes, HbA1c targets of <7% are recommended to reduce microvascular complications 4
• Higher targets (>7%) may be appropriate for patients with history of severe hypoglycemia, limited life expectancy, advanced complications, or certain comorbidities 8
• In patients with advanced chronic kidney disease, extreme HbA1c targets (<6.5% or >11%) are associated with increased mortality risk 7

Monitoring Recommendations

• Regular HbA1c testing is recommended for all patients with diabetes 4
• Testing frequency should be at least twice yearly for patients meeting treatment goals with stable glycemic control 4
• Quarterly assessment is recommended for patients whose therapy has changed or who are not meeting glycemic goals 4
• When HbA1c results seem discordant with clinical picture, consider potential confounding factors and alternative monitoring methods 2

Discrepancy Between High HbA1c and Optimal Self-Monitored Blood Glucose Readings

Common Causes of HbA1c-SMBG Discrepancy

• Operator-related errors are a more significant source of error than instrument-related errors in SMBG, according to the American Medical Association 9
• Common technique errors include improper calibration of glucose meters, poor hand washing, dirty meters, and improper storage of test strips, as reported by the American Medical Association 9
• Limited testing frequency may miss significant glycemic excursions, particularly postprandial hyperglycemia, as noted by the American Medical Association 10
• Conditions affecting red blood cell lifespan alter HbA1c independent of glycemia, such as shortened RBC lifespan or prolonged RBC lifespan, as stated by the American Diabetes Association 11

Evaluation Steps

• Evaluate the patient's monitoring technique, as operator-related errors are a significant source of inaccuracy, according to the American Medical Association 9
• Review the frequency and timing of SMBG - inadequate testing may miss significant glycemic excursions, as reported by the American Diabetes Association 12
• Check if the patient is testing during postprandial periods, as these may be more predictive of overall glycemic control in some patients, as noted by the American Medical Association 10

Management Recommendations

• Provide robust diabetes education on proper SMBG technique, as recommended by the American Medical Association 9
• Increase testing frequency, especially for insulin-treated patients, as suggested by the American Diabetes Association 12
• Implement structured testing at various times of day, including fasting, pre-meal, post-meal, and bedtime readings, as recommended by the American Medical Association 10
• Consider continuous glucose monitoring (CGM) to better understand glycemic patterns and identify missed excursions, as suggested by the American Diabetes Association 12
• Consider alternative measures of glycemic control such as fructosamine if HbA1c is suspected to be unreliable, as stated by the American Diabetes Association 11

Management of Falsely Elevated HbA1c

Initial Verification Steps

• The American Diabetes Association guidelines recommend repeating the HbA1c test without delay using the same laboratory method to rule out laboratory error before confirming any diabetes diagnosis, especially when the initial HbA1c result is elevated but discordant with clinical presentation 13, 14
• If the repeat HbA1c remains elevated but discordant with clinical presentation, proceed to alternative testing rather than waiting 3-6 months, as recommended by the American Diabetes Association 13, 15

Diagnostic Algorithm for Discordant Results

• If HbA1c is ≥6.5% but fasting glucose <126 mg/dL, repeat HbA1c immediately using the same laboratory method, as suggested by the American Diabetes Association guidelines 13, 14
• For conditions with abnormal RBC turnover, such as hemolytic anemia, chronic kidney disease, pregnancy, or recent blood loss/transfusion, use only glucose-based criteria for diagnosis, as HbA1c is unreliable, according to the American Diabetes Association 15, 16

Critical Pitfalls to Avoid

• Never diagnose diabetes based on a single HbA1c without confirmation, especially when clinical presentation doesn't match, as emphasized by the American Diabetes Association guidelines 13, 14
• Avoid using point-of-care HbA1c for diagnostic decisions due to lack of standardization, as recommended by the American Diabetes Association 14, 16

HbA1c as the Preferred Indicator for Chronic Glycemic Assessment

Diagnostic Use

• The American Diabetes Association (ADA) recommends using an HbA1c ≥ 6.5 % as the primary diagnostic criterion for diabetes, performed in a certified laboratory; repeat testing or a fasting glucose ≥ 126 mg/dL is advised when results are borderline or discordant. High‑quality evidence supports this approach. 17

• When conditions that alter red‑blood‑cell turnover (e.g., hemoglobin variants, hemolytic anemia, chronic kidney disease, pregnancy, recent transfusion) may render HbA1c unreliable, the ADA advises using glucose‑based criteria (fasting plasma glucose or oral glucose tolerance test) instead. Strong evidence from guideline consensus. 17

Monitoring and Therapeutic Targets

• The ADA recommends HbA1c as the primary tool for ongoing diabetes management, with testing at least twice yearly for stable patients and quarterly for patients not meeting goals or after therapy changes. Level A evidence (large prospective studies) underpins this recommendation. [18][17]

• For most non‑pregnant adults, the ADA sets a target HbA1c < 7 % to reduce the risk of microvascular complications; this target is based on robust outcome data linking lower HbA1c to fewer retinopathy, nephropathy, and neuropathy events. Strong evidence. [18][17]

• While fasting blood sugar (FBS) or random blood sugar (RBS) may be used for day‑to‑day treatment adjustments (e.g., insulin dosing), the ADA emphasizes that they must not replace HbA1c for assessing overall glycemic control. Consensus guideline. 18

• In insulin‑treated individuals, the ADA suggests complementing HbA1c with continuous glucose monitoring (CGM) or frequent self‑monitoring of blood glucose to capture glycemic variability and hypoglycemia that HbA1c cannot reflect. Evidence from recent trials. [18][17]

Assay Standardization

• HbA1c assays are standardized and certified as traceable to the DCCT reference method, ensuring consistency across laboratories worldwide. This standardization is endorsed by the ADA and is based on high‑quality methodological evidence. 19

Limitations of Other Glycemic Markers

• HbA1c is the only glycemic marker with robust evidence demonstrating direct relationships with both microvascular (retinopathy, nephropathy, neuropathy) and macrovascular disease. Large cohort studies provide Level A evidence for these associations. [19][18]

• The correlation between HbA1c and mean plasma glucose is strong (r = 0.92), as shown in the landmark ADAG study, confirming its accuracy as a surrogate for average glucose. High‑quality evidence. 17

Alternative Markers When HbA1c Is Unreliable

• Hemoglobin variants (e.g., HbS, HbC) and altered red‑cell lifespan (hemolytic anemia, chronic kidney disease, pregnancy, iron‑deficiency anemia) can cause falsely low or high HbA1c values. In such scenarios, the ADA recommends using glycated serum protein assays (fructosamine, glycated albumin), which reflect glycemia over the preceding 2–4 weeks. Consensus guideline. [17][19]

• Glycated serum protein markers have not been shown to relate to the risk of chronic complications (e.g., retinopathy, nephropathy) in the way HbA1c does, based on systematic reviews and cohort data. Moderate‑quality evidence. [19][20]

• These alternative markers are useful for short‑term monitoring after major therapy changes or when HbA1c is unreliable, but they should not replace HbA1c for routine chronic monitoring. Guideline consensus. [19][20]17